Keywords: Merck & Co, Brinavess, Zostavax, Shingles, Herpes, Cadiome Pharma

Merck & Co/Cardiome’s Brinavess shows superiority to amiodarone in Ph III AF trial; Zostavax safety confirmed

Article | 18 May 2010

Print This

US drug giant Merck & Co says that a new Phase III study with Brinavess (vernakalant) intravenous, an investigational compound ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in